Browse studies

Find your next paid study

849 recruiting studies matching your filters

Pilot Study of 64Cu-DOTA Pembrolizumab (64CDP) in Patients Receiving Stereotactic Body Radiation Therapy (SBRT) for Oligo-Progressive Non-Small Cell Lung Cancer (NSCLC)

This phase I trial studies the safety and side effects of a new positron emission tomography (PET) imaging agent called 64Cu-DOTA-pembrolizumab to see how well…

Metastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainOligoprogressive Lung Non-Small Cell Carcinoma+1 more

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT07619599

Observational

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (G…

Chronic Graft Versus Host DiseaseAcute Graft Versus Host DiseaseHematopoietic and Lymphatic System Neoplasm

Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT07535008

The Impact of DNA Repair Pathway Alterations Identified by Circulating Tumor DNA on Sensitivity to Radium-223 in Bone Metastatic Castration-Resistant Prostate Cancer

This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases)…

Castration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Prostate Carcinoma+1 more

Estimated

~$10 – $750

University of WashingtonNCT04489719

Phase 1

A First-in-Human, Phase 1 Dose Escalation and Dose Expansion Trial to Assess the Safety and Tolerability of COM503 as Monotherapy and in Combination Therapy in Participants With Advanced Solid Malignancies

The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberel…

NeoplasmCancer, Malignant Tumors

Estimated

~$10 – $8,750

Compugen LtdNCT06759649

Phase 2

Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids

This phase II trial studies whether psilocybin with psychotherapy is safe and if it works for improving chronic pain in cancer patients who require opioids to …

Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm

Estimated

~$10 – $7,500

Roswell Park Cancer InstituteNCT06827054

Phase 1

A Phase 1 Safety and Efficacy Study of JV-394 Autologous Anti-CD94 Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed or Refractory CD94+ T/NK Cell Neoplasms

The goal of this clinical research study is to find the highest tolerable dose of JV-394 (a type of autologous CAR-T cell therapy) that can be given to patient…

Neoplasms

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07382817

Self-Monitoring Focus Groups With Vibrant Lives Pasadena Participants

This study investigates how individuals feel about a dietary mobile application. Information collected from focus groups and interviews may help doctors and mo…

Obesity-Related Malignant Neoplasm

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT04611087

Observational

Precision Clinical Trial Recruitment to Promote Cancer Health Equity Across Florida (Aims 2 & 3)

This clinical trial studies how well a virtual community health educator (vCHE) works in increasing clinical trial referrals for patients with cancer and their…

Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm

Estimated

~$10 – $6,250

Mayo ClinicNCT07126496

Observational

Measuring the Effectiveness of a Continuous Positive Airway Pressure (CPAP) Device to Reduce Tumor Motion and Increase Lung Volume Expansion in Patients Undergoing Stereotactic Body Radiotherapy (SBRT) for Tumors That Move With Respiration

This pilot phase I/II trial studies how well a continuous positive airway pressure device or deep inspiration breath hold works in reducing tumor movement in p…

Lung CarcinomaMalignant Respiratory Tract NeoplasmMetastatic Malignant Neoplasm in the Lung

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT03422302

Phase 1

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in co…

Advanced Solid TumorsGenital Neoplasm, FemaleUrogenital Neoplasms+11 more

Estimated

~$10 – $8,750

Marengo Therapeutics, Inc.NCT05592626

Phase 2

IZABRIGHT-Breast01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase in…

Breast Neoplasms

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT06926868

The Impact of COVID-19 on Pulmonary Procedures: A Nationwide Survey

This study investigates the changes in practice by pulmonary procedural programs across the United States as they faced the coronavirus pandemic. Information g…

COVID-19 InfectionHematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT05022446